All data are based on the daily closing price as of December 20, 2024
e

EuBiologics

206650.KQ
8.20 USD
-0.18
-2.15%

Overview

Last close
8.20 usd
Market cap
298.81M usd
52 week high
12.49 usd
52 week low
4.99 usd
Target price
10.38 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
6.2518
Price/Book Value
3.4992
Enterprise Value
297.83M usd
EV/Revenue
6.2025
EV/EBITDA
58.0351

Key financials

Revenue TTM
48.02M usd
Gross Profit TTM
N/A usd
EBITDA TTM
11.68M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
N/A usd
Net debt
N/A usd

About

EuBiologics Co., Ltd., a biopharmaceutical company, provides vaccines for epidemics in South Korea. It offers Euvichol Plus, an oral cholera prevention vaccine; and rCRM197, a diphtheria toxoid vaccine. The company also provides EcML, a vaccine for cell membrane, as well as offers COVID-19 diagnostic kits. In addition, it offers CMO services comprising of drug product production, cell bank production, and drug substance production. Further, the company provides CRMO services, including cell line development, GMP production, validation, and the regulatory support; and operates facilities that manufacture protein-based therapeutics and antibodies. Additionally, it offers contract testing services that include lot release, stability, raw material, and method validation testing services. EuBiologics Co., Ltd. was founded in 2010 and is headquartered in Seoul, South Korea.
  • Symbol
    206650.KQ
  • Exchange
    KQ
  • Isin
    N/A
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
  • Headquarter
    Seoul
  • Web site
    https://www.eubiologics.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top